PepGen Inc., commonly referred to as PEPG, is a biotechnology company that has been making remarkable strides in the development of transformative therapeutics for rare, life-threatening diseases, particularly those related to the nervous system.
Founded in Oxford, UK, the team at PepGen has achieved significant advancements in the field of biotechnology since its inception. The company has made use of cutting-edge scientific technology to drive its vision of finding reliable and effective treatments for patients suffering from serious genetic diseases.
PepGen's primary focus is on the design and development of Enhanced Delivery Oligonucleotide (EDO) therapeutics. EDOs are a new breed of medicine which holds substantial therapeutic potential. This groundbreaking technology has proven to be particularly beneficial when it comes to efficiently and accurately delivering genetic medicine to the right parts of the body. EDO technology is key to PepGen's strategy, and the company is dedicated to further unlocking its potential to treat a variety of serious diseases.
With its proprietary EDO technology, PepGen doesn't only focus on treating the symptoms of these detrimental diseases, but it seeks to address these conditions at their roots. The team behind PepGen comprises of industry leaders and highly skilled professionals who share the same vision of bringing innovative treatments to the patients who need them the most.
One of the many diseases PepGen is focusing on is Duchenne Muscular Dystrophy (DMD), a devastating genetic disorder affecting young boys that results in muscle degeneration and premature death. The company's transformative therapeutics offer hope to these patients by providing a potential targeted treatment option.
Additionally, PepGen is not just confined to DMD but it is also aiming to create treatment options for neurological disorders like Huntington's Disease and ALS, also known as Lou Gehrig's disease.
Overall, PepGen Inc. is setting new standards in the field of biotechnology with its pioneering research and technology. Its focus on rare genetic diseases and its dedication to developing treatments offers hope to those suffering from diseases that currently have limited or no treatment options. As PepGen continues its mission to break new ground, expectations are high for what the company will achieve in the coming years.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
GSA Capital Partners LLP has initiated a new investment in PepGen, Inc. (NASDAQ:PEPG), acquiring 852,852 shares valued at approximately $1.535 million, representing a 1.23% stake. This investment comes as institutional ownership in PepGen collectively stands at 58.01%. The company recently reported better-than-expected quarterly EPS of -$0.26, and analysts maintain a "Moderate Buy" rating with an average price target of $11.50.
PepGen, Inc. (NASDAQ:PEPG) has received a "Moderate Buy" consensus rating from seven research firms, with an average 12-month price target of $11.50. Institutional investors hold 58.01% of the stock, with several funds increasing their positions recently. The company reported a quarterly loss of $0.26 per share, beating analyst estimates.
HC Wainwright has updated its financial outlook for PepGen, raising the FY2027 EPS estimate to a loss of $1.78 per share and maintaining a "Buy" rating. The firm also projects a $1.33-per-share loss for FY2029. PepGen currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $11.50, and recently reported quarterly EPS of $(0.26), beating consensus estimates.
PepGen (Nasdaq: PEPG) reported a narrowed net loss of $17.8 million for Q2 2026, down from $23.1 million in Q2 2025, primarily due to a significant reduction in R&D expenses. The company ended the quarter with $117.2 million in cash and expects these funds to last into Q4 2027. Investor focus is now on the upcoming clinical trial data for PGN-EDODM1, with results for the 10 mg/kg FREEDOM2 cohort anticipated in November and higher-dose results in the first half of 2027.